Food Tech Insider

What’s moving the food technology industry forward.

The most telling moment in food tech this week wasn’t a flashy funding round or a lab-grown breakthrough. It was a quiet £5.4 million acquisition — and who was missing from it.

Hilton Food Group, one of Europe’s largest meat processors, just sold its private-label vegan business to LIVEKINDLY Collective. That’s two plant-based exits by a major protein player inside five weeks if you’re counting. Meanwhile, LIVEKINDLY is snapping up European manufacturing capacity at what looks like a serious discount. Read those tea leaves however you like, but the message is hard to miss: the plant-based shakeout isn’t coming — it’s here, and the winners are already buying up the pieces.

But here’s what I keep thinking about. While the plant-based narrative gets retold as consolidation and caution, the broader food-tech story is quietly branching in directions most newsletters aren’t connecting.

Take Wildtype. They hit their Kickstarter for cellular salmon, which on its own isn’t shocking — cultivated seafood has had its believers for years. What caught my eye is where their cellular material is now turning up: skincare. When a cell-ag company starts landing in cosmetics aisles, it stops being just a food story. It becomes a feedstock story.

And the feedstock theme keeps deepening. Ponda just landed £2.35M from DEFRA to farm bulrush on rewetted wetlands — for insulation that debuted at London Fashion Week. The EU dropped €7M on the Salina project to scale seaweed biorefineries across food, cosmetics, and biomaterials. Health Canada just cleared Rhiza mycoprotein for use across blended meat, seafood, and dairy. Three different governments, three different organisms, one shared thesis: the next wave of alternative proteins and biomaterials won’t come from a single silver-bullet crop but from a messy, distributed portfolio of fermentation, macroalgae, paludiculture, and mycelium.

So what’s actually at stake? I’d argue it’s no longer “will plant-based win?” — that question already fractured. The real question is which of these parallel tracks convert public funding and crowdfunded enthusiasm into commercial reality before the novelty discount closes. Cellular agriculture is finding revenue in personal care. Mycoprotein is lining up 2027 launches. Seaweed is being industrialised. This is the part of the cycle where bets get made — and where the next decade of the sector’s structure quietly crystallises.

Here’s what stood out this morning.

Today’s Headlines

I’ll search for the latest food technology news in parallel with multiple queries to get broad coverage.I have good initial coverage. Let me dig deeper into a few specific stories to verify details and find additional updates.I have rich detail on multiple stories. Let me get a couple more confirmations on the Ponda UK government funding and the Salina seaweed project for a well-rounded list.I have enough verified stories. Here’s the structured digest:

Latest Food Technology News (Last 24-48 Hours)

1. LIVEKINDLY Collective Acquires Dalco Food in $7.3M Deal

• URL: https://www.greenqueen.com.hk/livekindly-collective-dalco-hilton-food-group-plant-based-meat-acquisition
• Source: Green Queen
• Summary: LIVEKINDLY Collective has agreed to acquire Dalco Food, Hilton Food Group’s Dutch private-label vegan/vegetarian business, for £5.4M ($7.3M). The deal closes on the heels of LIVEKINDLY’s July 1 agreement to buy Germany’s Greenforce Future Food — its second plant-based acquisition in five weeks.
• Why it matters: Hilton is signaling exit from plant-based (focusing on “core” meat and seafood), while LIVEKINDLY is consolidating European plant-based manufacturing capacity at a discount. ^1

2. Wildtype Cellular Salmon Surpasses Kickstarter Crowdfunding Target

• URL: https://cultivatedbites.substack.com/p/the-month-in-cultivated-meat-july-6be
• Source: Cultivated Bites (Substack)
• Summary: Cultivated seafood startup Wildtype surpassed its Kickstarter crowdfunding target with $90,000 raised from over 285 backers, supporting commercialisation of its cell-cultured salmon. Wildtype’s cellular material has also begun appearing in skincare applications, signalling cross-sector demand for cell-ag outputs.
• Why it matters: Crowdfunding success validates consumer appetite for cultivated seafood ahead of broader regulatory and retail scale-up. ^2

3. BMC Ingredients Wins Health Canada Clearance for Rhiza Mycoprotein

• URL: https://www.greenqueen.com.hk/bmc-ingredients-the-better-meat-co-rhiza-mycoprotein-health-canada-approval
• Source: Green Queen
• Summary: Health Canada issued a Letter of No Objection for Rhiza mycoprotein — BMC Ingredients’ fungi-fermented whole-food mycelium — clearing it for use as an alternative protein and dietary fibre source across blended meat, seafood, meat-analog, and dairy products. CEO Paul Shapiro confirmed the company is targeting Q2 2027 for large-scale commercial volumes from an Asian contract manufacturer (100 dry tonnes/month capacity).
• Why it matters: Rhiza now has clearances in three key regulatory markets, positioning it for a meaningful 2027 commercial launch in the competitive mycoprotein space. ^3

4. Ponda Wins £2.35M DEFRA Grant to Scale Wetland-Based Biomaterials

• URL: https://www.greenqueen.com.hk/ponda-biopuff-paluduff-paludiculture-wetland-farming-uk-defra-funding-biomaterials
• Source: Green Queen
• Summary: The UK’s Department for Environment, Food and Rural Affairs (Defra) awarded £2.35M to a 30-month project led by Bristol-based biomaterials startup Ponda to establish a 30-hectare paludiculture demonstration site for cultivating bulrush (typha). The consortium — including Liverpool John Moores University, Berghaus, and J&K Barnard Farms — aims to scale feedstock for Ponda’s BioPuff plant-based insulation, which debuted at London Fashion Week on July 29.
• Why it matters: Government-backed paludiculture signals real commercial potential for wetland-farmed feedstocks across food, materials, and fashion rather than remaining a research novelty. ^4

5. EU Funds €7M Salina Project for Seaweed-Based Novel Foods

• URL: https://www.greenqueen.com.hk/salina-project-eu-seaweed-macroalgae-food-cosmetics-biomaterials
• Source: Green Queen
• Summary: The EU’s Circular Bio-based Europe Joint Undertaking (CBE JU) has committed €7M to Salina, a multinational project to build scalable macroalgae cultivation systems and marine biorefineries producing seaweed-derived alternatives for food, cosmetics, and biomaterials. A separate €5.7M CBE JU tranche went to Alganova for a microalgae biorefinery fed on waste and CO₂.
• Why it matters: Seaweed is at the centre of Europe’s strategy for low-carbon alternative proteins and bio-based materials, with substantial public capital now backing commercial scale-up. ^5

6. Wildtype Cellular Material Enters Skincare — Industry Cross-Application

• URL: https://www.greenqueen.com.hk/future-food-quick-bites-protein-mac-cheese-wildtype-funding-meat-sales
• Source: Green Queen (Future Food Quick Bites, weekly column)
• Summary: The weekly digest also notes new product activity — including Daiya’s protein mac and cheese — alongside the broader Wildtype cultivated salmon story. Wildtype’s cellular material making its way into cosmetics illustrates how cell-ag outputs are crossing beyond food applications into personal care.
• Why it matters: Food-tech outputs breaking into adjacent industries could expand the addressable market for cellular agriculture beyond edible protein. ^6

Want me to consolidate this into a written digest file you can keep in the workspace, or send it somewhere (email/Telegram) for distribution?

Final Thoughts

The Wrap

Today’s stories circle a single theme: consolidation and capital flowing toward alternative proteins and bio-based materials, even as legacy players retreat. LIVEKINDLY snapped up two European plants in five weeks while Hilton Food Group exited — and public money backed seaweed, mycoprotein, and wetland crops from Brussels to Bristol.

That split is the real signal. Plant-based isn’t dying; it’s reorganising around fewer, better-funded operators while new feedstocks (mycelium, macroalgae, bulrush) quietly build regulatory roadmaps toward 2027 commercial volumes. Watch whether Wildtype’s skincare crossover becomes a trend or a one-off, and whether Rhiza hits its Q2 2027 ramp without a food-safety stumble.

What are you tracking — the consolidation play, the novel-ingredient pipeline, or something deeper in the cell-ag crossover?

Compiled from industry sources. All credits and links provided above.